Page 326 - Haematologica March 2020

C. Becattini et al.
patients not randomized to anticoagulant prophylaxis (95% CI: 5-7; I2=91%). In these studies, anticoagulant prophylaxis reduced the incidence of VTE (OR=0.45, 95% CI: 0.36-0.56; I2=5%) (Figure 1).
phylaxis with parenteral anticoagulants (11 studies, 6,700 patients; OR=0.43, 95% CI: 0.33-0.56; I2=0%) and oral agents (3 studies, 1,526 patients; OR=0.49, 95% CI: 0.33- 0.74; I2=57%) was associated with the same magnitude of reduction of VTE risk. However, significant heterogeneity
Figure 1. Efficacy of anticoagulant prophylaxis for the prevention of venous thromboembolism in ambulatory cancer patients receiving chemotherapy. (A) Analysis of studies having venous thromboembolism or death as the primary outcome. (B) Analysis of studies with parenteral or oral anti- coagulants. *Warfarin was used for prophyaxis in one study.19
Among studies with VTE as the primary outcome, pro-
A
B
840
haematologica | 2020; 105(3)